Daily Stock Analysis, ATHX, Athersys Inc, priceseries

Athersys Inc. Daily Stock Analysis
Stock Information
Open
1.59
Close
1.64
High
1.65
Low
1.58
Previous Close
1.60
Daily Price Gain
0.04
YTD High
2.03
YTD High Date
May 16, 2019
YTD Low
1.35
YTD Low Date
Apr 18, 2019
YTD Price Change
0.16
YTD Gain
10.81%
52 Week High
2.23
52 Week High Date
Sep 26, 2018
52 Week Low
1.35
52 Week Low Date
Apr 18, 2019
52 Week Price Change
-0.42
52 Week Gain
-20.39%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 27. 2017
1.17
Apr 6. 2017
1.47
8 Trading Days
25.27%
Link
LONG
Aug 28. 2017
1.70
Sep 12. 2017
1.87
10 Trading Days
10.07%
Link
LONG
Sep 13. 2017
2.01
Sep 27. 2017
2.31
10 Trading Days
15.14%
Link
LONG
Mar 9. 2018
1.56
Mar 27. 2018
1.86
12 Trading Days
19.54%
Link
LONG
Sep 21. 2018
1.94
Oct 10. 2018
2.06
13 Trading Days
6.38%
Link
Company Information
Stock Symbol
ATHX
Exchange
NasdaqCM
Company URL
http://www.athersys.com
Company Phone
216-431-9900
CEO
Gil van Bokkelen
Headquarters
Ohio
Business Address
3201 CARNEGIE AVENUE, CLEVELAND, OH 44115-2634
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001368148
About

Athersys, Inc. is a biotechnology company, which focuses in the field of regenerative medicine and engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.